News & Updates
Filter by Specialty:
Secukinumab: Fewer jabs do the job in psoriasis
New data presented at EADV 2021 support the efficacy of secukinumab 300-mg dose in a 2-mL autoinjector compared with two 150 mg in 1 mL pre-filled syringes or placebo for psoriasis, with no new safety signals observed within 52 weeks.
Secukinumab: Fewer jabs do the job in psoriasis
12 Oct 2021
Recovered mothers transfer SARS-CoV-2 antibodies to newborns
A Hong Kong study demonstrates vertical transfer of antibodies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to babies whose mothers have recovered from coronavirus disease 2019 (COVID-19).
Recovered mothers transfer SARS-CoV-2 antibodies to newborns
12 Oct 2021
Early convalescent plasma infusion does not prevent COVID-19 progression
An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.
Early convalescent plasma infusion does not prevent COVID-19 progression
11 Oct 2021
Diet plus exercise keeps BP in check for patients with resistant hypertension
A structured lifestyle modification programme that combines a healthy eating plan and regular aerobic exercise promotes blood pressure (BP) control and improves cardiovascular disease biomarkers in patients with resistant hypertension, as shown in the TRIUMPH study.
Diet plus exercise keeps BP in check for patients with resistant hypertension
11 Oct 2021
POETYK trials highlight potential of novel drug for plaque psoriasis
The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.